MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Kodu・Aktsiate loetelu・Insmed

Insmed

Suletud

SektorTervishoid

173.6 -0.25

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

172.54

Max

175.09

Põhinäitajad
By Trading Economics
Sissetulek	-48M -370M
Müük	35M 142M
Kasumimarginaal	-259.952
Töötajad	1,271
EBITDA	-49M -344M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+25.83% upside

Turustatistika
By TradingEconomics
Turukapital	2.7B 38B
Eelmine avamishind	173.85
Eelmine sulgemishind	173.6

Uudiste sentiment

By Acuity

100%

358 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

N/A / 69.2 Toetus ja vastupanu

Insmed Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. dets 2025, 23:50 UTC

Kuumad aktsiad

Stocks to Watch: Micron, MillerKnoll, HireQuest, Insmed

10. juuni 2025, 12:53 UTC

Suurimad hinnamuutused turgudel

Insmed Shares Rise on Positive Results From Study of Treatment for High Blood Pressure in Lungs

Võrdlus sarnastega

Hinnamuutus

Insmed Prognoos

Hinnasiht

By TipRanks

25.83% tõus

12 kuu keskmine prognoos

Keskmine 219 USD 25.83%

Kõrge 263 USD

Madal 158 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Insmed 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

17 ratings

Osta

Hoia

Müü

Põhineb 17 analüütiku instrumendi Insmed aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 69.2Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

358 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.